

# Richard Kajubi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11023739/publications.pdf>

Version: 2024-02-01

27  
papers

324  
citations

932766

10  
h-index

839053

18  
g-index

27  
all docs

27  
docs citations

27  
times ranked

410  
citing authors

#	ARTICLE	IF	CITATIONS
1	Piperaquine-Induced QTc Prolongation Decreases With Repeated Monthly Dihydroartemisinin-Piperaquine Dosing in Pregnant Ugandan Women. <i>Clinical Infectious Diseases</i> , 2022, 75, 406-415.	2.9	8
2	Gestational age dating using newborn metabolic screening: A validation study in Busia, Uganda. <i>Journal of Global Health</i> , 2021, 11, 04012.	1.2	2
3	Age-Related Changes in Malaria Clinical Phenotypes During Infancy Are Modified by Sickle Cell Trait. <i>Clinical Infectious Diseases</i> , 2021, 73, 1887-1895.	2.9	4
4	Generation of a malaria negative Ugandan birth weight standard for the diagnosis of small for gestational age. <i>PLoS ONE</i> , 2020, 15, e0240157.	1.1	4
5	Piperaquine Exposure Is Altered by Pregnancy, HIV, and Nutritional Status in Ugandan Women. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	3
6	Associations between Malaria-Preventive Regimens and Plasmodium falciparum Drug Resistance-Mediating Polymorphisms in Ugandan Pregnant Women. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	10
7	Overall, anti-malarial, and non-malarial effect of intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine on birthweight: a mediation analysis. <i>The Lancet Global Health</i> , 2020, 8, e942-e953.	2.9	37
8	Impact of intermittent preventive treatment of malaria in pregnancy with dihydroartemisinin-piperaquine versus sulfadoxine-pyrimethamine on the incidence of malaria in infancy: a randomized controlled trial. <i>BMC Medicine</i> , 2020, 18, 207.	2.3	16
9	Infant sex modifies associations between placental malaria and risk of malaria in infancy. <i>Malaria Journal</i> , 2020, 19, 449.	0.8	6
10	Determination of piperaquine concentration in human plasma and the correlation of capillary versus venous plasma concentrations. <i>PLoS ONE</i> , 2020, 15, e0233893.	1.1	6
11	Relationships Between Measures of Malaria at Delivery and Adverse Birth Outcomes in a High-Transmission Area of Uganda. <i>Journal of Infectious Diseases</i> , 2020, 222, 863-870.	1.9	11
12	Title is missing!. , 2020, 15, e0233893.		0
13	Title is missing!. , 2020, 15, e0233893.		0
14	Title is missing!. , 2020, 15, e0233893.		0
15	Title is missing!. , 2020, 15, e0233893.		0
16	Title is missing!. , 2020, 15, e0233893.		0
17	Title is missing!. , 2020, 15, e0233893.		0
18	Reduced Exposure to Piperaquine, Compared to Adults, in Young Children Receiving Dihydroartemisinin+Piperaquine as Malaria Chemoprevention. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1310-1318.	2.3	4

#	ARTICLE	IF	CITATIONS
19	Household and maternal risk factors for malaria in pregnancy in a highly endemic area of Uganda: a prospective cohort study. <i>Malaria Journal</i> , 2019, 18, 144.	0.8	21
20	Impact of Microscopic and Submicroscopic Parasitemia During Pregnancy on Placental Malaria in a High-Transmission Setting in Uganda. <i>Journal of Infectious Diseases</i> , 2019, 220, 457-466.	1.9	18
21	Monthly sulfadoxine-pyrimethamine versus dihydroartemisinin-piperazine for intermittent preventive treatment of malaria in pregnancy: a double-blind, randomised, controlled, superiority trial. <i>Lancet</i> , 2019, 393, 1428-1439.	6.3	76
22	Modeling Prevention of Malaria and Selection of Drug Resistance with Different Dosing Schedules of Dihydroartemisinin-Piperazine Preventive Therapy during Pregnancy in Uganda. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	14
23	Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperazine. <i>Clinical Infectious Diseases</i> , 2018, 67, 1079-1088.	2.9	19
24	Strong correlation of lumefantrine concentrations in capillary and venous plasma from malaria patients. <i>PLoS ONE</i> , 2018, 13, e0202082.	1.1	4
25	Parasite Clearance and Artemether Pharmacokinetics Parameters Over the Course of Artemether-Lumefantrine Treatment for Malaria in Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Ugandan Children. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw217.	0.4	6
26	Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children. <i>Clinical Infectious Diseases</i> , 2016, 63, 414-422.	2.9	29
27	Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1274-1282.	1.4	26